Tag: Pharmaceutical marketing laws

Online Graduate Certificate Program in Pharmaceutical & Medical Device Law & Compliance, ‘Bringing Products to Market,’ to Start on Oct. 7, 2012

Filed in Compliance, Health Law by on September 12, 2012 0 Comments
Online Graduate Certificate Program in Pharmaceutical & Medical Device Law & Compliance, ‘Bringing Products to Market,’ to Start on Oct. 7, 2012
Share

Through its Center for Health & Pharmaceutical Law & Policy, Seton Hall Law School offers 3 graduate certificate programs in Pharmaceutical & Medical Device Law & Compliance. These flexible, 8-week certificate programs are designed for professionals seeking to enhance their knowledge about legal, regulatory, and ethical issues within the pharmaceutical and medical device industries. Featuring […]

Share

Continue Reading »

Another Multi-Billion-Dollar Settlement for Pharma

Filed in Uncategorized by on July 5, 2012 0 Comments
Another Multi-Billion-Dollar Settlement for Pharma
Share

As reaction to the Supreme Court’s decision on the Affordable Care Act (“ACA”) continues to make headlines with mind-numbing political arguments surrounding the distinction (or lack thereof) between a “tax” and a “penalty,” healthcare fraud enforcement rolls on unchanged.  This week brought news of yet another pharmaceutical company entering into an eye-popping settlement following damning […]

Share

Continue Reading »

Kate Greenwood on American Law Journal TV Regarding Off-Label Promotion

Filed in Drugs & Devices by on March 18, 2012 0 Comments
Kate Greenwood on American Law Journal TV Regarding Off-Label Promotion
Share

In Case you missed it: Research Fellow & Lecturer in Law, Seton Hall Law’s Center for Health & Pharmaceutical Law & Policy, Kate Greenwood, on American Law Journal TV regarding Pharmaceutical Off-Label Marketing and Free Speech. A regular blogger here at HRW, Kate Greenwood appeared along with attorneys Hope Freiwald of Dechert, LLP and Brian […]

Share

Continue Reading »

Recommended Reading: Recent Scholarship on Drug and Device Regulation

Filed in Recommended Reading by on December 1, 2011 0 Comments
Recommended Reading: Recent Scholarship on Drug and Device Regulation
Share

In Patients Over Politics: Addressing Legislative Failure in the Regulation of Medical Products (forthcoming in the 2011 volume of the Wisconsin Law Review and available on SSRN), Efthimios Parasidis proposes a significant expansion of drug and device companies’ responsibility to engage in “active post-market analysis” of drugs and devices, to be coupled with a new […]

Share

Continue Reading »

Does the Ban on Off-Label Promotion Bar On-Label Promotion?: The Case of Call Plans

Filed in Uncategorized by on November 6, 2011 2 Comments
Does the Ban on Off-Label Promotion Bar On-Label Promotion?: The Case of Call Plans
Share

As predicted, in the wake of the Supreme Court’s decision in Sorrell v. IMS Health pharmaceutical companies have raised First Amendment challenges to the ban on off-label promotion on a number of fronts.  Most recently, Par Pharmaceutical sued to invalidate the ban to the extent that it “criminalize[s] Par’s truthful and non-misleading speech to healthcare […]

Share

Continue Reading »